Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cryoglobulinemia vasculitis: how to handle.

Anne C Desbois1, Cloe Comarmond, David Saadoun

  • 1aSorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B) bINSERM, UMR_S 959 cCNRS, FRE3632 dAP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Paris, France.

Current Opinion in Rheumatology
|April 4, 2017
PubMed
Summary

New direct-acting antivirals (DAAs) offer a highly effective and safe treatment for hepatitis C virus (HCV)-associated cryoglobulinemia vasculitis (CryoVas), marking a significant advance in patient care.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PDE4 inhibitor mitigates activated CD8+ T cells through NF-κB signaling in Behçet's syndrome.

Frontiers in immunology·2026
Same author

Long-term outcomes and prognosis of mixed cryoglobulinaemia: a European multicentre study of 1294 patients.

Rheumatology (Oxford, England)·2026
Same author

Treat-to-target in Behçet syndrome.

Nature reviews. Rheumatology·2026
Same author

French recommendations for the use of imaging in giant cell arteritis.

Joint bone spine·2026
Same author

Clonal haematopoiesis of indeterminate potential and relapses in patients with GCA.

Rheumatology (Oxford, England)·2026
Same author

Takayasu arteritis phenotypes and outcomes: A data-driven cluster analysis from a large international cohort.

Journal of autoimmunity·2026

Area of Science:

  • Hepatology
  • Immunology
  • Rheumatology

Background:

  • Hepatitis C virus (HCV) infection frequently leads to mixed cryoglobulinemia.
  • Over two-thirds of patients with mixed cryoglobulinemia develop symptomatic cryoglobulinemia vasculitis (CryoVas).

Purpose of the Study:

  • To review recent diagnostic and therapeutic advancements for HCV-associated CryoVas.
  • To highlight the impact of novel antiviral therapies on managing this complication.

Main Methods:

  • Review of current literature on HCV-CryoVas diagnosis and treatment.
  • Analysis of recent clinical findings and consensus recommendations.

Main Results:

  • Direct-acting antivirals (DAAs) have revolutionized HCV-CryoVas treatment, offering high cure rates and excellent safety.

Related Experiment Videos

  • Interferon-free DAAs are now recommended as first-line therapy for most HCV-CryoVas patients.
  • Immunosuppressive agents remain crucial for severe cases or when antiviral therapy is contraindicated.

    • Conclusions:

    • DAAs provide a well-tolerated and definitive treatment for the majority of HCV-CryoVas patients.
    • This represents a major clinical advancement, improving outcomes for a previously challenging complication.